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1Brief  Communications
Headache as the Presenting Symptom in 2 Patients With 
COVID-19 and a History of  Migraine: 2 Case Reports
Jyotika Singh, DO ; Ashhar Ali, DO
The coronavirus disease 2019 (COVID-19) pandemic has now affected more than 5  million people globally. Typical symp-
toms include fever, cough, and shortness of breath. Patients with underlying medical comorbidities such as cardiovascular disease 
and diabetes are more likely to become severely ill. To date there is limited information on how COVID-19 affects patients 
with a history migraine. Here, we present the cases of 2 women with a history of migraine whose first symptom of COVID-19 
was a severe persistent headache.
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BACKGROUND
Coronavirus disease 2019 (COVID-19), which 
emerged in Wuhan, China in December, 2019, is now 
a global pandemic. It is a part of the coronavirus 
family, and uses the angiotensin-converting enzyme 2 
(ACE-2) receptor to enter cells and can cause severe 
acute respiratory syndrome.1 The median incubation 
period before one shows typical symptoms is estimated 
to be 5.1  days, but one may not show symptoms for 
up to 14 days.2 While the most common symptoms of 
COVID-19 are fever, cough, and shortness of breath, 
neurological symptoms including headache have been 
reported. In 1 study, headache was noted in 12% of con-
firmed cases and was the most common neurological 
symptom.3 In another study, from Wuhan, the epicen-
ter of the outbreak, headache was reported as the sec-
ond most common neurologic symptom after dizziness 
and was present in 13% of patients .4 Other less com-
mon neurological manifestations included anosmia, 
ageusia, ischemic infarct, and impaired consciousness.4
The mechanism by which COVID-19 causes head-
ache remains unclear. One may postulate that its mech-
anism is like other respiratory viruses such as influenza 
A and B, in which headache often accompanies fever 
and fatigue.5 There are also reports that COVID-19 
has neuroinvasive potential via various pathways.1 The 
ACE-2 receptor, through which COVID-19 appears to 
cause infection, is primarily present in epithelium of 
the lungs; however, it is also found in the brain, partic-
ularly the brainstem.6 Another postulated mechanism 
of entry into the brain may be through the olfactory 
bulb via trans-synaptic route.6 It has been noted that 
patients with more severe disease are more likely to have 
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CNS involvement.7 Interestingly, couple recent studies 
have demonstrated changes in magnetic resonance im-
aging of the brain in patients with COVID-19 infec-
tion admitted to the ICU. Noted were cortical signal 
abnormalities on FLAIR imaging, cortical diffusion 
restriction, bilateral frontotemporal hypoperfusion, 
leptomeningeal enhancement, and cortical blooming 
artifact. It remains unclear if  these findings are due to 
neuro-invasion with COVID-19 itself  or as a second-
ary effect of systemic infection with COVID-19.8,9
Given its prevalence, many patients with migraine 
have and will be infected with COVID-19. Their expe-
rience with the disease has not yet been reported. Here, 
we illustrate the cases of 2 patients – 1 with episodic 
migraine and 1 with chronic migraine – whom devel-
oped severe headache whilst infected with COVID-19. 
Of note, in both cases, the patients developed daily 
headache several days prior to the onset of typical 
symptoms of COVID-19.
CASE 1
A 31-year-old female has a history of episodic 
migraine since age 5. Her migraine attacks occur once 
to twice per month, are unilateral, throbbing in qual-
ity, moderate to severe in intensity, and are associated 
with photophonophobia and nausea. They typically last 
2-8 hours with treatment. She developed a moderate to 
severe daily headache which she described as distinct 
from her usual migraine. It was a continuous, pounding, 
bilateral frontotemporal headache that was moderate to 
severe in intensity. She did not have photophonophobia 
or nausea. The headache would briefly improve with ibu-
profen 400 mg, but would recur the following day. One 
week later, she developed fever, cough, severe myalgias, 
dyspnea, and diarrhea. She tested positive for COVID-
19 via nasopharyngeal swab PCR. Once diagnosed, out 
of fear that her COVID-19 would be exacerbated by the 
use of non-steroid anti-inflammatory drugs (NSAIDs), 
she switched to acetaminophen without improvement. 
After consulting with a headache specialist, she was 
advised to take naproxen 440 mg twice daily as needed 
as well as tizanidine 4 mg every 8 hours as needed. The 
patient opted not to take tizanidine and only took 2 
doses of naproxen, with which she saw no improve-
ment and discontinued the use due to the apprehension 
of worsening infection. Both her classical symptoms of 
COVID-19 and headache resolved 4 days after diagnosis 
and she did not undergo repeat testing for COVID-19.
CASE 2
A 32-year-old female has a history of chronic 
migraine and is currently on topiramate 50 mg nightly 
for prophylaxis and sumatriptan 50  mg for abortive 
therapy. Her migraine attacks occur 2-3 times per week 
and are bifrontal, throbbing in quality, severe in in-
tensity, and associated with photophonophobia and 
nausea. Her migraine attacks typically last >24 hours 
if  untreated. She developed a severe intractable head-
ache 1 week prior to the onset of typical COVID-19 
symptoms. The headache was different than her usual 
migraine. It was more intense, persistent, and not re-
sponsive to abortive therapy. She took acetaminophen 
daily without relief. Sumatriptan, her usual abortive 
treatment, was also not effective. One week later, she 
developed typical COVID-19 symptoms which con-
sisted of low-grade fever, myalgias, nasal congestion, 
anosmia, and diarrhea. She tested positive for COVID-
19 via nasopharyngeal swab PCR. After 2 to 3 days, 
these symptoms resolved, but her headache persisted. 
She was seen by a headache specialist via a telemedi-
cine video visit 2 weeks after onset of her severe head-
ache and 1 week after the onset of typical COVID-19 
symptoms. Her topiramate was increased to 100  mg 
nightly, her sumatriptan was switched to rizatriptan, 
and she was started on tizanidine 4 mg every 8 hours as 
needed for breakthrough pain. Two days after starting 
this regimen, the patient’s headache resolved. Repeat 
COVID-19 testing via nasophyaryngeal swab was per-
formed and was negative, 5  weeks after she initially 
tested positive.
DISCUSSION
The above 2 cases demonstrate headache as the 
first symptom of COVID-19 infection in patients with 
a history of migraine. Interestingly, the phenomenon 
of headache as an early symptom of COVID-19 infec-
tion was also noted by Mao et al. The authors describe 
patients who had symptoms of fever and headache. 
They were initially considered negative for COVID-19 
infection through normal bloodwork and negative lung 
computed tomography (CT). However, several days 
later, they developed typical COVID-19 symptoms, 
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low lymphocyte count, and typical findings associated 
with COVID-19 on lung CT; the patients ultimately 
tested positive for COVID-19 via PCR. It is unclear, 
however, if  these patients had a history of migraine.4 
At this time, while we lack sufficient data to conclude 
that headache is an early symptom of COVID-19 
infection, we recommend that in areas where COVID-19 
is endemic, patients with a new type of headache take 
additional precautions.
In our patients, the headache preceding typical 
COVID-19 symptoms was distinct from the patients’ 
usual migraine, alluding to the possibility that head-
ache related to COVID-19 is mechanistically differ-
ent than migraine. These headaches were described 
as more severe, unrelenting, and not as responsive to 
the patients’ usual abortive treatments. It is possible 
that headache is a manifestation of COVID-19 CNS 
invasion or cytokine storm, though further data are 
needed.6
There were some differences between these 2 pa-
tients. Notably, the first patient’s headache resolved 
with the resolution of other COVID-19 symptoms, 
while the second patient continued to have headaches 
for 2 weeks after the resolution of typical COVID-19 
symptoms. Furthermore, our first patient did not have 
migrainous features with her continuous headache, but 
our second patient did.
Many patients infected with COVID-19 have 
underlying medical conditions. Often highlighted 
in the medical literature and mainstream media are 
the co-morbidities that are associated with increased 
mortality, such as cardiovascular disease, obesity, 
and diabetes.10 However, with the high prevalence 
of  migraine in the general population, and as it is 
a leading cause of  disability, it too is an underlying 
medical condition that warrants academic and clini-
cal attention.11 This includes a better understanding 
of  the headache that occurs with COVID-19 – its 
qualities, characteristics, and true incidence. It also 
includes the need for larger retrospective studies eval-
uating the experience of  COVID-19 in patients with 
a history of  a primary headache disorder. Our expe-
rience with the above 2 cases suggests that migraine 
patients, particularly young healthy women wherein 
migraine is most prevalent, may be more disabled 
by COVID-19 infection compared with age-matched 
cohorts, most of  whom will only experience mild 
symptoms.12
Further investigation and discussion are also 
needed on the safety of commonly used headache 
treatments. There has been concern regarding the use 
of NSAIDs, due to anecdotal evidence citing worsen-
ing of COVID-19 symptoms in young patients who re-
ceived treatment with NSAIDs early in the disease.13 
However, there is no clinical or population-data that 
corroborates this risk, and hence, both the European 
Medicines Agency and World Health Organization 
(WHO) have not recommended that NSAIDs be 
avoided.14,15 Despite this recommendation, as a pre-
cautionary measure many providers have opted to 
avoid NSAIDs in patients with COVID-19. This car-
ries several implications for the headache popula-
tion. Our first patient self-discontinued her abortive 
therapy, ibuprofen, out of caution, and also chose to 
limit naproxen intake. Anecdotally, many non-infected 
patients at our headache center have expressed concern 
over continuing their NSAID abortive therapy during 
the pandemic. One patient on indomethacin for par-
oxysmal hemicrania raised concern about its continua-
tion. As more data are collected, we will be better able 
to assess the risks. Nonetheless, in a recent article about 
migraine care in the era of COVID-19, Dr. Szperka 
et al recommend continued the use of certain NSAIDs 
(Indomethacin, ketorolac, naproxen, nabumetone, 
diclofenac, and mefenamic acid) as abortive treatment 
for migraine.16 In our practice, the decision to continue 
or stop NSAIDs in patients with COVID-19 is made 
in collaboration between the treating physician and the 
patient, after a brief  discussion on the limited available 
evidence. Most patients tend to err on the side of cau-
tion. More data are needed, however, before broad rec-
ommendations are made.
Other considerations that affect our migraine pop-
ulation include limited access to care, be it in-person 
office visits, intravenous infusions, procedures such 
as nerve blocks or onabotulinumtoxinA injections. 
We have shared our experience in delaying certain in- 
person care in a recent publication.17
CONCLUSION
Further studies are needed to better understand 
the implications of headache in COVID-19 patients. 
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The above 2 cases demonstrate that patients with a his-
tory migraine may experience headache as their first 
symptom, and due to severe headache, may be more 
disabled by the infection compared with age-matched 
cohorts. Until we have more data, healthcare provid-
ers caring for these patients should prepare treatment 
plans to optimally manage headache during COVID-
19 infection. This is of particular importance given the 
limited access to in-person evaluations and concerns by 
both providers and patients alike regarding the safety 
of NSAIDs.
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